The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.

Read more about BAP

Summer Meeting 2017

Join us in Harrogate 23rd to 26th July 2017
Read More

Antidepressants and Suicide

Prof Carmine Pariante attended House of Commons Health Select Committee regarding antidepressants and suicide
Read More

Metabolic Guidelines Article

Article on the recent metabolic guidelines by Peter Haddad, Gavin Reynolds and Stephen Cooper
Read More

Dementia Guidelines Meeting

Clinical Practice with Anti-Dementia Drugs: Updated Guidelines from the BAP, 19th January 2017
Read More

Fundamentals Wins BMA Award

Fundamentals of Clinical Psychopharmacology wins BMA Medical Book Award in Psychiatry
Read More

Fundamentals of Clinical Psychopharmacology

Buy a discounted copy of the new Fundamentals of Clinical Psychopharmacology
Read More

Online CPD Resource

RCPsych Online CPD Subscribers get a discount on the BAP Online Resource
Read More

New world order: Brexit, drugs and research

Letter to House of Commons Science and Technology Committee
Read More

The Ten Secrets of Success in Science

View Professor Trevor Robbins presenting his top tips
Read More

Neuroscience-based Nomenclature (NbN) for JoP

Journal of Psychopharmacology chosen to trial new NbN
Read More

Benefits of BAP membership include:

  • FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
  • Reduced registration fees for the annual Summer Meeting.
  • Half price subscription to the Online CPD Resource.
  • Eligibility for prizes and awards.
  • Student bursaries for the BAP Summer Meeting and international conferences.
  • Reduced registration fees for selected partner association events.
  • 50% OFF Royal Society of Biology membership (Read more)
  • BAP Newsletter.
  • Voting for BAP Officers and Council (full members only).
  • Being part of one of the largest national psychopharmacology associations in the world.


From the House of Commons to the Daily Mail, but with the same message: antidepressants save lives
By Carmine Pariante
Posted on 8th March 2017

Antidepressants are always in the news, but the messages coming across are often contradictory. In most countries the use of antidepressants has increased since the year 2000 (although so has the use of anti-hypertension and anti-diabetes medications), yet worldwide less than a fourth of people with depression receive adequate treatment. Some patients are coming forward […]

Genetic insights into psychiatric disorders
By Simon Trent
Posted on 5th March 2017

Psychiatric disorders such as schizophrenia, autism spectrum disorders (ASD) and major mood disorders are common, with 1 in 100 people affected by schizophrenia and a lifetime prevalence of 10% for major depressive disorder. They are highly debilitating to the patient and have a profound impact on the patient’s family, as well as society in general. […]

Is Cannabidiol a useful drug for treating addictions?
By Chandni Hindocha
Posted on 5th March 2017

Molecular structure of CBD cannabidiolAnecdotal evidence suggests that people are using Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, to help them quit smoking cigarettes as well as other drugs. At the same time, emerging research suggests that CBD indeed might be a novel treatment to treat addictions. However, the research itself is sparse and we do not have […]

See more articles


Tom Freeman
Can we make cannabis safer?
Tom and co-author Amir talk to Editor Niall Boyce about cannabis harm reduction
1st March 2017

Ciara McCabe
The Emotional Brain: The 14th Oxford Brain Day
Ciara speaks about her work on depression and antidepressants treatments for Oxford Brain Day
25th February 2017

Carmine Pariante
Antidepressants may not be perfect, but they DO save lives
Carmine writes for the Daily Mail showing how, when used correctly, antidepressants do work
21st February 2017

Andrew Mayers
Unexpected deaths of mental health patients in Dorset up 50% in three years
Andrew is interviewed by Bournemouth Echo about increases in unexpected deaths related to mental health
16th February 2017

Stephen Lawrie
Why schizophrenia need not rob us of a life in academia
Stephen is interviewed by the Guardian regarding working in academia with a mental illness
1st February 2017

See more media


Anti-Dementia Drugs Guidelines Updated
20th January 2017

The third revision of BAP Guidelines, 'Clinical practice with anti-dementia drugs', are now available for download.
View Guidelines
ACMD report on Diversion and Illicit Supply of Medicines
19th December 2016

BAP contributed evidence to the ACMD – Diversion & Illicit Supply of Medicines Inquiry
View letter and report
British Medical Association (BMA) Research Grants 2017
16th December 2016

Applications are open 5th December from medical doctors or research scientists working in the UK for BMA research grants.
More information
Professor David Nutt receives honorary degree from Bath University
8th December 2016

BAP warmly congratulates Professor David Nutt, who has been awarded Degree of Doctor of Laws, honoris causa, from Bath University.
Read More

See more news


Psychopharmacology is the study of drugs that affect mood, behaviour and cognition. It aims to develop our understanding of the actions and effects of such drugs, which may include treatments for psychiatric disorders as well as substances that can be abused.